PLNR≤20% may be a benefit from PORT for patients with IIIA-N2 NSCLC: a large population-based study

References

• ChenWZhengRBaadePDCancer statistics in China, 2015CA Cancer J Clin201666211513226808342
   PubMed Web of Science ®Google Scholar
• MolinaJRYangPCassiviSDSchildSEAdjeiAANon-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and SurvivorshipMayo Clin Proc200883558459418452692
   PubMed Web of Science ®Google Scholar
• Cancer Council Australia Lung Cancer Guidelines Working PartyClinical practice guidelines for the treatment of lung cancer Available from: http://wiki.cancer.org.au/australia/Guidelines:Lung_cancerAccessed April 22, 2016
   Google Scholar
• DecaluwéHde LeynPVansteenkisteJSurgical multimodality treatment for baseline resectable stage IIIA-N2 non-small cell lung cancer. Degree of mediastinal lymph node involvement and impact on survivalEur J Cardiothorac Surg200936343343919502079
   PubMed Web of Science ®Google Scholar
• StefaniAAlifanoMBobbioAWhich patients should be operated on after induction chemotherapy for N2 non-small cell lung cancer? Analysis of a 7-year experience in 175 patientsJ Thorac Cardiovasc Surg2010140235636320381815
   PubMed Web of Science ®Google Scholar
• PaulSMirzaFPortJLSurvival of patients with clinical stage IIIA non-small cell lung cancer after induction therapy: age, mediastinal downstaging, and extent of pulmonary resection as independent predictorsJ Thorac Cardiovasc Surg20111411485821092990
   PubMed Web of Science ®Google Scholar
• KappersIvan SandickJWBurgersSABelderbosJSvan ZandwijkNKlompHMSurgery after induction chemotherapy in stage IIIA-N2 non-small cell lung cancer: why pneumonectomy should be avoidedLung Cancer201068222222719664843
   PubMed Web of Science ®Google Scholar
• MolinaJRYangPCassiviSDSchildSEAdjeiAANon-small cell lung cancer: epidemiology, risk factors, treatment, and survivorshipMayo Clin Proc200883558459418452692
   PubMed Web of Science ®Google Scholar
• ArriagadaRBergmanBDunantAInternational Adjuvant Lung cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancerN Engl J Med200435035136014736927
   PubMed Web of Science ®Google Scholar
• WintonTLivingstonRJohnsonDVinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancerN Engl J Med2005352252589259715972865
   PubMed Web of Science ®Google Scholar
• DouillardJYRosellRde LenaMAdjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trialLancet Oncol20067971972716945766
   PubMed Web of Science ®Google Scholar
• JonnalagaddaSArcinegaJSmithCWisniveskyJPValidation of the lymph node ratio as a prognostic factor in patients with N1 nonsmall cell lung cancerCancer2011117204724473121452193
   PubMed Web of Science ®Google Scholar
• MatsugumaHOkiINakaharaRProposal of new nodal classifications for non-small-cell lung cancer based on the number and ratio of metastatic lymph nodesEur J Cardiothorac Surg2012411192421620720
   PubMed Web of Science ®Google Scholar
• NwoguCEGromanAFaheyDNumber of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancerAnn Thorac Surg20129351614162022440365
   PubMed Web of Science ®Google Scholar
• WangCLLiYYueDSZhangLMZhangZFSunBSValue of the metastatic lymph node ratio for predicting the prognosis of non-small- cell lung cancer patientsWorld J Surg201236245546222187129
   PubMed Web of Science ®Google Scholar
• RenaudSFalcozP-EOllandAReebJSantelmoNMassardGMediastinal downstaging after induction treatment is not a significant prognostic factor to select patients who would benefit from surgery: the clinical value of the lymph node ratioInteract Cardiovasc Thorac Surg201520222222725413781
   PubMed Web of Science ®Google Scholar
• WangSMaZYangXChoice of postoperative radiation for stage IIIA pathologic N2 non-small cell lung cancer: impact of metastatic lymph node numberRadiat Oncol201712120729284511
   PubMedGoogle Scholar
• Surveillance, Epidemiology, and End Results (SEER) ProgramSEER 17 Regs Public-Use, Nov 2006 Sub (1973–2004)NCI Available from:https://www.seer.cancer.govAccessed April 2007
   Google Scholar
• PORT Meta-analysis Trialists GroupPostoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists GroupLancet199835291242572639690404
   PubMed Web of Science ®Google Scholar
• WisniveskyJPHalmEABonomiMSmithCMhangoGBagiellaEPostoperative radiotherapy for elderly patients with stage III lung cancerCancer2012118184478448522331818
   PubMed Web of Science ®Google Scholar
• CorsoCDRutterCEWilsonLDKimAWDeckerRHHusainZARe-evaluation of the role of postoperative radiotherapy and the impact of radiation dose for non-small-cell lung cancer using the National Cancer DatabaseJ Thorac Oncol201510114815525325781
   PubMed Web of Science ®Google Scholar
• RobinsonCGPatelAPBradleyJDPostoperative radiotherapy for pathologic N2 non-small-cell lung cancer treated with adjuvant chemotherapy: a review of the National Cancer Data BaseJ Clin Oncol201533887087625667283
   PubMed Web of Science ®Google Scholar
• LallyBEZeltermanDColasantoJMHafftyBGDetterbeckFCWilsonLDPostoperative radiotherapy for stage II or III non-small- cell lung cancer using the surveillance, epidemiology, and end results databaseJ Clin Oncol200624192998300616769986
   PubMed Web of Science ®Google Scholar
• SawyerTEBonnerJAGouldPMEffectiveness of postoperative irradiation in stage IIIA non-small cell lung cancer according to regression tree analyses of recurrence risksAnn Thorac Surg1997645140214079386711
   PubMed Web of Science ®Google Scholar
• MachtayMLeeJHShragerJBKaiserLRGlatsteinERisk of death from intercurrent disease is not excessively increased by modern postoperative radiotherapy for high-risk resected non-small-cell lung carcinomaJ Clin Oncol200119193912391711579111
   PubMed Web of Science ®Google Scholar
• DouillardJYRosellRde LenaMImpact of postoperative radiation therapy on survival in patients with complete resection and stage I, II, or IIIA non-small-cell lung cancer treated with adjuvant chemotherapy: the adjuvant Navelbine International Trialist Association (ANITA) Randomized TrialInt J Radiat Oncol Biol Phys200872369570118439766
   PubMed Web of Science ®Google Scholar
• FengWZhangQFuX-LThe emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volumeBMC Cancer201515134825934006
   PubMedGoogle Scholar
• Le PéchouxCDunantAFaivre-FinnCPostoperative Radiotherapy for Pathologic N2 Non-Small-Cell Lung Cancer Treated With Adjuvant Chemotherapy: Need for Randomized EvidenceJ Clin Oncol201533262930293126215941
   PubMed Web of Science ®Google Scholar
• AndreFGrunenwaldDPignonJPSurvival of patients with resected N2 non-small-cell lung cancer: evidence for a subclassification and implicationsJ Clin Oncol200018162981298910944131
   PubMed Web of Science ®Google Scholar
• ReifMSocinskiMARiveraMPEvidence-based medicine in the treatment of non-small cell lung cancerClin Chest Med20002110712010763093
   PubMed Web of Science ®Google Scholar
• RothJAFossellaFKomakiRA randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancerJ Natl Cancer Inst19948696736808158698
   PubMed Web of Science ®Google Scholar
• MantovaniCLevraNGFilippiARPostoperative radiotherapy for patients with completely resected pathologic n2 non-small-cell lung cancer: a retrospective analysisClin Lung Cancer201314219419922885347
   PubMed Web of Science ®Google Scholar
• MatsugumaHNakaharaRIshikawaYPostoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non- small cell lung cancer: focusing on an effect of the number of mediastinal lymph node stations involvedInteract Cardiovasc Thorac Surg20087457357718413349
   PubMedGoogle Scholar
• MorettiLYuDSChenHPrognostic factors for resected non- small cell lung cancer with pN2 status: implications for use of postoperative radiotherapyOncologist200914111106111519897534
   PubMed Web of Science ®Google Scholar
• CampRLDolled-FilhartMRimmDLX-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimizationClin Cancer Res200410217252725915534099
   PubMed Web of Science ®Google Scholar
• DemariaSFormentiSCRole of T lymphocytes in tumor response to radiotherapyFront Oncol201229522937524
   PubMedGoogle Scholar
• DoddoliCAragonABarlesiFDoes the extent of lymph node dissection influence outcome in patients with stage I non-small-cell lung cancer?Eur J Cardiothorac Surg200527468068515784374
   PubMed Web of Science ®Google Scholar
• WhitsonBAGrothSSMaddausMASurgical assessment and intra- operative management of mediastinal lymph nodes in non-small cell lung cancerAnn Thorac Surg20078431059106517720443
   PubMed Web of Science ®Google Scholar
• GajraANewmanNGambleGPKohmanLJGrazianoSLEffect of number of lymph nodes sampled on outcome in patients with stage I non-small-cell lung cancerJ Clin Oncol20032161029103412637467
   PubMed Web of Science ®Google Scholar
• TsaiYMHuangTWHsuHHPrognostic significance of the number of removed lymph nodes at lobectomy in patients with positron emission tomography-computed tomography-negative N2 non-small cell lung cancerOnkologie20133693623549030
   PubMedGoogle Scholar